Sartorius Viral Vectors Platform
Single-Use Technologies and Associated Services to Address the Process Development and Productions Needs of Manufacturers of Viral Vectors
Sartorius technologies are ideally suited for the production of viral vaccines, vectors and gene therapies. They allow end-to-end, single-use processing of viruses from process development through to commercial manufacturing at the 2000 L-scale. Manufacturers of virus-related products are benefiting from our unique upstream and downstream technologies, analytics and services including our process development consultancy, cost modelling and process engineering capabilities.
Gene therapy has become one of the most rapidly evolving and promising fields in regenerative medicine and has a wide range of potential applications, such as the treatment of hereditary genetic disorders, cancer and infectious diseases. Gene therapy mainly encompasses the use of a viral vector to introduce an intact gene, either directly into the patient (in vivo) or indirectly via transduction of cells before infusion into the patient (ex vivo), to reconstitute or modify a harmful gene variant.
The growing number of viral vectors used as clinical therapeutics will require scalable commercial upstream and downstream processes to be developed and optimized to ensure that critical quality attributes (CQAs) are retained.
Plasmid DNA (pDNA) is the starting point for the production of various next-generation biopharmaceuticals. However, pDNA molecules are larger and more sensitive than traditional modalities, creating a new set of manufacturing challenges
Explore the steps in a typical pDNA purification process
Understand the hurdles associated with efficient pDNA production, and discover how our solutions can help you overcome them